Louis J. Ignarro
Affiliations: | Molecular and Medical Pharmacology | University of California, Los Angeles, Los Angeles, CA |
Area:
regulation and modulation of nitric oxide (NO) production and cytotoxicity in macrophages, vascular cells, and tumor cellsWebsite:
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1998/ignarro-bio.htmlGoogle:
"Louis J. Ignarro"Bio:
http://www.nasonline.org/member-directory/members/3008579.html
http://faculty.pharmacology.ucla.edu/institution/personnel?personnel_id=45458
The Nobel Prize in Physiology or Medicine 1998 was awarded jointly to Robert F. Furchgott, Louis J. Ignarro and Ferid Murad for their discoveries concerning nitric oxide as a signalling molecule in the cardiovascular system
.
Mean distance: 13.9 | S | N | B | C | P |
Parents
Sign in to add mentor| Frederick E. Shideman | grad student | 1966 | UMN | |
| (Catecholamines and the Enzymes Involved in Their Synthesis and Metabolism in the Embryonic and Developing Chick) | ||||
| Elwood O. Titus | post-doc | 1966-1968 | NIH (NHLBI) | |
Children
Sign in to add trainee| Philip M. Bauer | grad student | 2001 | UCLA |
| Aaron T. Jacobs | grad student | 2003 | UCLA |
| Michael S. Wolin | post-doc | 1983 | Tulane University Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Karlsson JOG, Jynge P, Ignarro LJ. (2023) Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn and Oxaliplatin-Associated Pt. Antioxidants (Basel, Switzerland). 12 |
| Karlsson JOG, Jynge P, Ignarro LJ. (2021) The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx. Antioxidants (Basel, Switzerland). 10 |
| Ignarro LJ. (2021) Nitric Oxide: A Unique Endogenous Signaling Molecule in Vascular Biology (Nobel Lecture). Angewandte Chemie (International Ed. in English). 38: 1882-1892 |
| Dóka É, Arnér ESJ, Schmidt EE, et al. (2021) Comment on "Evidence that the ProPerDP method is inadequate for protein persulfidation detection due to lack of specificity". Science Advances. 7 |
| Karlsson JOG, Jynge P, Ignarro LJ. (2020) May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? Antioxidants (Basel, Switzerland). 9 |
| Ignarro LJ. (2020) Inhaled Nitric Oxide and COVID-19. British Journal of Pharmacology |
| Karlsson JOG, Jynge P, Lundström I, et al. (2019) Letter in response to: "Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial". Trials. 20: 380 |
| Ignarro LJ. (2019) Nitric oxide is not just blowing in the wind. British Journal of Pharmacology. 176: 131-134 |
| Fukuto JM, Ignarro LJ, Nagy P, et al. (2018) Biological Hydropersulfides and Related Polysulfides: A New Concept and Perspective in Redox Biology. Febs Letters |
| Karlsson JO, Ignarro LJ, Lundström I, et al. (2015) Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discovery Today. 20: 411-21 |